Boston Scientific (NYSE:BSX) wins CE Mark approval for improved longevity projections for its devices

Boston Scientific Corporation (NYSE:BSX) has been granted CE Mark approval for higher longevity estimates for the INCEPTA, ENERGEN, PUNCTUA, COGNIS and TELIGEN implantable cardioverter defibrillators, or ICDs, and cardiac resynchronization therapy defibrillators, or CRT-Ds.

The data presented to the European authorities was the basis of the longevity projections and may differ for all devices by depending on the model type and settings.

The projected device life is crosses ten years for some models of BSX ICDs and for its CRT-D devices it approach 8 years, and twice when compared with competitive device models.

Boston Scientific Corporation (NYSE:BSX) supports these devices with warranties of as long as 10 years. The device warranties are also up to double as long as other currently-marketed comparable devices, depending on the model.

According the Michael Onuscheck, senior VP  and president of Europe, Middle East and Africa at Boston Scientific, they are delighted with the new labeling for their defibrillator products which offers doctors and patients more assurance about the longevity of these devices.

Boston Scientific Corporation (NYSE:BSX) hit -55.27% as their profit margin for the last twelve months and had an operating margin of -52.41%. Evaluating management effectiveness, return on equity was maintained at -43.84% in last twelve months. Return on assets for Intel was -20.95%. In the previous 52 weeks the price has traded between $4.79 – $6.41. The last session’s volume of 10.16 million shares competed with the average daily trading volume of 15.79 million shares.

Within the industry, Medtronic, Inc. (NYSE:MDT) had a 19.87% profit margin in the last twelve months and an operating margin at 24.67%. Return on equity for this company was 19.12% in the last twelve months. Return on assets was 9.87%. In the last year the stock has moved within a range of $34.98 – $44.79. The last session’s volume of 3.13 million shares competed with the average daily trading volume of 4.53 million shares.

St. Jude Medical, Inc. (NYSE:STJ) recorded a profit margin of 13.67% for the prior 12 months and an operating margin at 18.64%. Return on equity for this stock was 16.49% while return on assets was 8.35%.

Within the industry, Stryker Corporation (NYSE:SYK) had a 22.88% profit margin in the last twelve months and an operating margin at 20.96%. Return on equity for this company was 17.95% in the last twelve months. Return on assets was 11.50%.